Controlled Strategies of Impurities

Impurities must be understood and controlled to protect patients and satisfy regulators, and the nitrosamine experience showed how a reactive, case-by-case approach leaves companies exposed. PharmExpert develops impurity control strategies aligned to ICH Q3A–D and M7, covering organic, inorganic, residual-solvent, elemental and potentially mutagenic (genotoxic) impurities.

The foundation is a systematic source map. We trace every credible route by which an impurity could form or be introduced — starting materials, reagents, solvents, catalysts, degradation, packaging, recovered materials, even supplier processes — because the impurities that cause crises are usually the ones nobody mapped.

Each impurity class is then assessed and controlled to the right framework: mutagenic impurities against ICH M7 (including nitrosamine risk evaluation and the threshold of toxicological concern), elemental impurities against ICH Q3D, and organic impurities and residual solvents against ICH Q3A–C. Control points, limits and analytical methods are set on a science- and risk-based footing.

The result is a documented, defensible control strategy that keeps impurities reliably within acceptable bounds across the lifecycle — and the analytical capability to monitor them, often at very low limits. Building this in from development, rather than discovering problems late, is both more efficient and far more robust.